Extraordinary Benefit of Regorafenib in Metastatic Cholangiocarcinoma: A Case Report
Current Cancer Drug Targets, cilt.26, sa.8, ss.1049-1053, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 26 Sayı: 8
- Basım Tarihi: 2026
- Doi Numarası: 10.2174/0115680096378189250422100120
- Dergi Adı: Current Cancer Drug Targets
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Chemical Abstracts Core, EMBASE, MEDLINE, Health Research Premium Collection (ProQuest)
- Sayfa Sayıları: ss.1049-1053
- Anahtar Kelimeler: Regorafenib, cholangiocarcinoma, FGFR2 mutation, multikinase inhibitor, biliary tract, targeted therapy
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Introduction/Background: Cholangiocarcinoma (CC) is a rare, aggressive cancer of the bile ducts with limited treatment advancements over recent decades. The five-year survival rate for CC remains low, around 10%, and even lower for advanced cases. Case Presentation: This case report discusses a 46-year-old woman with metastatic CC who achieved remarkable progression-free survival with regorafenib, a multikinase inhibitor typically used in other cancers. After multiple lines of treatment, regorafenib was given as a 7th-line therapy. Despite initial intolerance requiring dose reduction, the patient achieved 22 months of progression-free survival (PFS) with stable disease and partial regression in some areas. Her response to regorafenib significantly exceeded typical outcomes in the literature, where PFS generally ranges from 3 to 4 months. This improvement may be attributed to an FGFR2 mutation identified via next-generation sequencing, which regorafenib may effectively target. Conclusion: This case suggests that patients with FGFR2 mutations might benefit from regorafenib, warranting further studies to explore this associationAs can be applied as a promising target gene to develop drug resistance and remedial efficacy.